Ulcerative Colitis Clinical Trial
— OPTIMIZE-UCOfficial title:
OPTIMIZE-UC: Feasibility of a Multimodal Intervention Program to Optimize Treatment Outcomes in Ulcerative Colitis: A Prospective Pilot Study
This is a prospective, interventional pilot study to assess the feasibility and optimal timing of a multimodal intervention program in Ulcerative Colitis (UC) patients with active disease as well as in patients in remission. Secondly, to demonstrate the effects of a multimodal intervention program on individual patients level and therapy outcomes.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | October 1, 2024 |
Est. primary completion date | October 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years old; - Diagnosis of UC confirmed by clinical, endoscopic, and/or histological evidence prior to screening as per standard criteria; - Ability of subject to participate fully in all aspects of this project; - Written informed consent must be obtained and documented. Exclusion Criteria: - Suspicion of differential diagnosis of CD, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis; - Serious underlying disease other than UC that in the opinion of the investigator may interfere with the subject's ability to participate fully in the study or would compromise subject safety (such as history of malignancies, major neurological disorders, certain orthopedic impairments or any unstable, uncontrolled or severe systemic medical disorder); - History of alcohol or drug abuse that in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures; - History of psychiatric disorders that in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures; - If female, the subject is pregnant or lactating (< 1 year) or intending to become pregnant; - Immobilized patients who are not able to complete exercise intervention; - Illiteracy (disability to read and understand Dutch). |
Country | Name | City | State |
---|---|---|---|
Netherlands | Dorien Oomkens | Nijmegen |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Accrural | The percentage of approached, eligible participants that are included in the study. | 24 weeks | |
Primary | Attrition | The percentage of participants who stopped the program prematurely. | 24 weeks | |
Primary | Adherence to exercise program | Frequency of followed trainings | 24 weeks | |
Primary | Adherence to daily exercise goals | SQUASH questionnaire | 24 weeks | |
Primary | Satisfaction | Measured using a patient satisfaction questionnaire | 24 weeks | |
Primary | Safety | Measured by the number of adverse events occurring during the program | 24 weeks | |
Secondary | Change in Oxygen Consumption (VO2 max) | Indication of physical fitness | 1 year | |
Secondary | Change in 1 repitition measures | Indication of muscle strength | 1 year | |
Secondary | Change in body weight | Measured in kilograms | 1 year | |
Secondary | Change in fat-free mass | Measured with bioelectrical impedance analysis (BIA) | 1 year | |
Secondary | Change in nutritional status | Measured with Patient Generated Subjective Global Assessment (PG-SGA) | 1 year | |
Secondary | Change in mental health | Hospital Anxiety and Depression scale (HADS questionnaire) | 1 year | |
Secondary | Change in Work Productivity and Activity Impairment | Work Productivity and Activity Impairment Questionnaire (including WPAI-GH) | 1 year | |
Secondary | Change in 36-Item Short Form Health Survey (SF-36) score | Quality of life | 1 year | |
Secondary | Change in EuroQoL (EQ-5D-5L) score | Quality of life | 1 year | |
Secondary | Change in Inflammatory Bowel Disease Questionnaire score | Disease-related quality of life | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |